The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how healthcare technology for providers stocks fared in Q2, starting with Privia Health (NASDAQ:PRVA).
The healthcare technology sector provides software and data analytics to help hospitals and clinics streamline operations and improve patient outcomes, often through value-based care models. Future growth is expected as providers prioritize digital transformation to manage rising costs and patient demands. Tailwinds include the adoption of AI-driven tools and government incentives for digitization. There challenges as well, including long sales cycles and slow adoption by providers, who may be resistance to change. Tightening hospital budgets and cybersecurity threats are additional risks that could slow adoption.
The 5 healthcare technology for providers stocks we track reported a satisfactory Q2. As a group, revenues beat analysts’ consensus estimates by 4% while next quarter’s revenue guidance was in line.
Luckily, healthcare technology for providers stocks have performed well with share prices up 16% on average since the latest earnings results.
Privia Health (NASDAQ:PRVA)
Operating in 13 states and the District of Columbia with over 4,300 providers serving more than 4.8 million patients, Privia Health (NASDAQ:PRVA) is a technology-driven company that helps physicians optimize their practices, improve patient experiences, and transition to value-based care models.
Privia Health reported revenues of $521.2 million, up 23.4% year on year. This print exceeded analysts’ expectations by 10.9%. Overall, it was a strong quarter for the company with an impressive beat of analysts’ revenue and EPS estimates.
Privia Health scored the biggest analyst estimates beat but had the weakest full-year guidance update of the whole group. Unsurprisingly, the stock is up 29.3% since reporting and currently trades at $25.60.
Is now the time to buy Privia Health? Access our full analysis of the earnings results here, it’s free for active Edge members.
Best Q2: Omnicell (NASDAQ:OMCL)
Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.
Omnicell reported revenues of $290.6 million, up 5% year on year, outperforming analysts’ expectations by 4.9%. The business had a very strong quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
The market seems content with the results as the stock is up 2.6% since reporting. It currently trades at $30.50.
Is now the time to buy Omnicell? Access our full analysis of the earnings results here, it’s free for active Edge members.
Weakest Q2: Evolent Health (NYSE:EVH)
Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.
Evolent Health reported revenues of $444.3 million, down 31.3% year on year, falling short of analysts’ expectations by 3.3%. It was a softer quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and revenue guidance for next quarter missing analysts’ expectations.
Evolent Health delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 19.9% since the results and currently trades at $7.76.
Read our full analysis of Evolent Health’s results here.
Premier (NASDAQ:PINC)
Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes.
Premier reported revenues of $262.9 million, down 12.5% year on year. This result beat analysts’ expectations by 5%. Overall, it was a strong quarter as it also logged a beat of analysts’ EPS and revenue estimates.
The stock is up 14.6% since reporting and currently trades at $28.02.
Read our full, actionable report on Premier here, it’s free for active Edge members.
Astrana Health (NASDAQ:ASTH)
Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.
Astrana Health reported revenues of $654.8 million, up 34.7% year on year. This number surpassed analysts’ expectations by 2.7%. It was a strong quarter as it also produced revenue guidance for next quarter exceeding analysts’ expectations and a beat of analysts’ EPS estimates.
Astrana Health achieved the fastest revenue growth and highest full-year guidance raise among its peers. The stock is up 53.7% since reporting and currently trades at $32.99.
Read our full, actionable report on Astrana Health here, it’s free for active Edge members.
Market Update
The Fed’s interest rate hikes throughout 2022 and 2023 have successfully cooled post-pandemic inflation, bringing it closer to the 2% target. Inflationary pressures have eased without tipping the economy into a recession, suggesting a soft landing. This stability, paired with recent rate cuts (0.5% in September 2024 and 0.25% in November 2024), fueled a strong year for the stock market in 2024. The markets surged further after Donald Trump’s presidential victory in November, with major indices reaching record highs in the days following the election. Still, questions remain about the direction of economic policy, as potential tariffs and corporate tax changes add uncertainty for 2025.
Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.